COLL — Collegium Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $765.06m
- $1.85bn
- $780.57m
Collegium Pharmaceutical Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Collegium Pharmaceutical Q3 Revenue USD 159.3 Million Vs. IBES Estimate USD 155.6 Million
Brief: Collegium Completes Acquisition Of Ironshore Therapeutics
Collegium Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary
Brief: Collegium Pharmaceutical Q2 Revenue USD 145.3 Million Vs. IBES Estimate USD 143.9 Million
Brief: Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
Brief: Collegium Obtains Six Month Extension Of U.S. Pediatric Exclusivity For Nucynta Franchise
U.S. RESEARCH ROUNDUP-Ciena, Huntsman, Prog Holdings
Brief: Collegium Announces $35 Mln Accelerated Share Repurchase Program
U.S. STOCKS ON THE MOVE-H&R Block, McDonald, Groupon
U.S. STOCKS ON THE MOVE-Victoria's Secret, Mettler-Toledo, Dropbox
Collegium falls on lower-than-expected Q1 revenue
Collegium Pharmaceutical Inc reports results for the quarter ended in March - Earnings Summary
Brief: Collegium Announces CEO Transition
Brief: Collegium Pharmaceutical Q1 Revenue USD 144.9 Million Vs. IBES Estimate USD 146.9 Million
Collegium Pharmaceutical Inc expected to post earnings of 73 cents a share - Earnings Preview
Brief: Collegium Announces Authorized Agreement With Hikma Pharmaceuticals USA For Nucynta
Brief: Collegium Pharmaceutical Announces Redemption Of Outstanding 2.625% Convertible Senior Notes Due 2026
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra